GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer

Healthcare is timely and personal – and its delivery should be too

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.

Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod

Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis

Novartis Scemblix shows better result for chronic myeloid leukemia trial

Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks

Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel

The drug will be manufactured at the group’s topical facility at Ahmedabad

NewAmsterdam Pharma shares new data from Phase 2b ROSE Study

82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo

MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib

he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients

Proxygen and Merck collaborates to develop molecular glue degraders

The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.

Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital

The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.

Ovensa and Celanese to collaborate to advance precision drug delivery